S Matthijs Boekholdt

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/2807150/s-matthijs-boekholdt-publications-by-year.pdf
Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

240 papers	18,691 citations	61 h-index	134 g-index
256 ext. papers	21,374 ext. citations	7.8 avg, IF	5.95 L-index

#	Paper	IF	Citations
240	Response to: Correspondence on "Lipoprotein(a) has no major impact on calcification activity in patients with mild to moderate aortic valve stenosis" by Pantelidis et al.. *Heart*, **2022**,	5.1	
239	Lipoprotein(a) has no major impact on calcification activity in patients with mild to moderate aortic valve stenosis. *Heart*, **2022**, 108, 61-66	5.1	3
238	Standardizing the Cardiac Radioablation Targeting Workflow: Enabling Semi-Automated Angulation and Segmentation of the Heart According to the American Heart Association Segmented Model.. *Advances in Radiation Oncology*, **2022**, 7, 100928	3.3	0
237	Confirmatory factor analysis including MRI-derived adipose tissues quantification improves associations of metabolic dysregulation to diastolic dysfunction.. *Journal of Diabetes and Its Complications*, **2022**, 36, 108202	3.2	
236	Midline crossing pulmonary vein: right upper lobe dual venous drainage, with partial anomalous venous return of the right lung into a persistent left superior vena cava. *Surgical and Radiologic Anatomy*, **2021**, 1	1.4	
235	Retrospective Camera-Based Respiratory Gating in Clinical Whole-Heart 4D Flow MRI. *Journal of Magnetic Resonance Imaging*, **2021**, 54, 440-451	5.6	2
234	Multimodality Evaluation of a Septal Cystic Cavity and Ventricular Septal Defect in the Setting of Neurocysticercosis and Endocarditis. *Circulation: Cardiovascular Imaging*, **2021**, 14, e011688	3.9	
233	Lipoprotein(a) is robustly associated with aortic valve calcium. *Heart*, **2021**, 107, 1422-1428	5.1	5
232	Plasma trimethylamine N-oxide (TMAO) levels predict future risk of coronary artery disease in apparently healthy individuals in the EPIC-Norfolk prospective population study. *American Heart Journal*, **2021**, 236, 80-86	4.9	7
231	Association between serum secretory phospholipase A2 and risk of ischaemic stroke. *European Journal of Neurology*, **2021**, 28, 3650-3655	6	1
230	Association of Circulating Monocyte Chemoattractant Protein-1 Levels With Cardiovascular Mortality: A Meta-analysis of Population-Based Studies. *JAMA Cardiology*, **2021**, 6, 587-592	16.2	8
229	Quantification of Myocardial Creatine and Triglyceride Content in the Human Heart: Precision and Accuracy of in vivo Proton Magnetic Resonance Spectroscopy. *Journal of Magnetic Resonance Imaging*, **2021**, 54, 411-420	5.6	2
228	Fully quantitative mapping of abnormal aortic velocity and wall shear stress direction in patients with bicuspid aortic valves and repaired coarctation using 4D flow cardiovascular magnetic resonance. *Journal of Cardiovascular Magnetic Resonance*, **2021**, 23, 9	6.9	3
227	Sex-Specific Associations of Genetically Predicted Circulating Lp(a) (Lipoprotein(a)) and Hepatic Gene Expression Levels With Cardiovascular Outcomes: Mendelian Randomization and Observational Analyses. *Circulation Genomic and Precision Medicine*, **2021**, 14, e003271	5.2	2
226	Impact of cholesterol on proinflammatory monocyte production by the bone marrow. *European Heart Journal*, **2021**, 42, 4309-4320	9.5	8
225	Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. *Nature Genetics*, **2021**, 53, 128-134	36.3	35
224	The impact and challenges of implementing CTCA according to the 2019 ESC guidelines on chronic coronary syndromes: a survey and projection of CTCA services in the Netherlands.. *Insights Into Imaging*, **2021**, 12, 186	5.6	0

223	Quantification of Mitral Valve Regurgitation from 4D Flow MRI Using Semiautomated Flow Tracking. *Radiology: Cardiothoracic Imaging*, **2020**, 2, e200004	8.3	2
222	Subclinical effects of long-chain fatty acid β-oxidation deficiency on the adult heart: A case-control magnetic resonance study. *Journal of Inherited Metabolic Disease*, **2020**, 43, 969-980	5.4	4
221	CT angiography vs echocardiography for detection of cardiac thrombi in ischemic stroke: a systematic review and meta-analysis. *Journal of Neurology*, **2020**, 267, 1793-1801	5.5	13
220	Genetic and In-Vitro Inhibition of and Calcific Aortic Valve Stenosis. *JACC Basic To Translational Science*, **2020**, 5, 649-661	8.7	18
219	Lipoprotein-associated phospholipase A2 activity, genetics and calcific aortic valve stenosis in humans. *Heart*, **2020**, 106, 1407-1412	5.1	3
218	Association of Long-term Exposure to Elevated Lipoprotein(a) Levels With Parental Life Span, Chronic Disease-Free Survival, and Mortality Risk: A Mendelian Randomization Analysis. *JAMA Network Open*, **2020**, 3, e200129	10.4	14
217	Outcomes of cardiac surgery after mediastinal radiation therapy: A single-center experience. *Journal of Cardiac Surgery*, **2020**, 35, 612-619	1.3	4
216	A pooled-analysis of age and sex based coronary artery calcium scores percentiles. *Journal of Cardiovascular Computed Tomography*, **2020**, 14, 414-420	2.8	4
215	Association of FADS1/2 Locus Variants and Polyunsaturated Fatty Acids With Aortic Stenosis. *JAMA Cardiology*, **2020**, 5, 694-702	16.2	7
214	Lifestyle modification in older versus younger patients with coronary artery disease. *Heart*, **2020**, 106, 1066-1072	5.1	5
213	Aortic dissection masquerading as a code stroke: A single-centre cohort study. *European Stroke Journal*, **2020**, 5, 56-62	5.6	5
212	Improved cardiovascular risk prediction using targeted plasma proteomics in primary prevention. *European Heart Journal*, **2020**, 41, 3998-4007	9.5	26
211	Mind the Heart: Electrocardiography-gated cardiac computed tomography-angiography in acute ischaemic stroke-rationale and study design. *European Stroke Journal*, **2020**, 5, 441-448	5.6	1
210	Effect of Spironolactone on Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: Post-Hoc Analysis of the Randomized, Placebo-Controlled TOPCAT Trial. *American Journal of Cardiovascular Drugs*, **2020**, 20, 73-80	4	11
209	Circulating Monocyte Chemoattractant Protein-1 and Risk of Stroke: Meta-Analysis of Population-Based Studies Involving 17 180 Individuals. *Circulation Research*, **2019**, 125, 773-782	15.7	47
208	Myocardial infarction with non-obstructive coronary arteries: a focus on vasospastic angina. *Netherlands Heart Journal*, **2019**, 27, 237-245	2.2	14
207	Genetic Variation in LPA, Calcific Aortic Valve Stenosis in Patients Undergoing Cardiac Surgery, and Familial Risk of Aortic Valve Microcalcification. *JAMA Cardiology*, **2019**, 4, 620-627	16.2	17
206	Body mass index and body fat distribution and new-onset atrial fibrillation: Substudy of the European Prospective Investigation into Cancer and Nutrition in Norfolk (EPIC-Norfolk) study. *Nutrition, Metabolism and Cardiovascular Diseases*, **2019**, 29, 692-700	4.5	5

205	Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis. *Journal of the American College of Cardiology*, **2019**, 73, 2150-2162	15.1	97
204	A 3-SNP gene risk score and a metabolic risk score both predict hypertriglyceridemia and cardiovascular disease risk. *Journal of Clinical Lipidology*, **2019**, 13, 492-501	4.9	0
203	Abnormal blood flow and wall shear stress are present in corrected aortic coarctation despite successful surgical repair. *Journal of Cardiovascular Surgery*, **2019**, 60, 152-154	0.7	4
202	Bileaflet mechanical aortic valves do not alter ascending aortic wall shear stress. *International Journal of Cardiovascular Imaging*, **2019**, 35, 703-710	2.5	4
201	apoB/apoA-I Ratio and Lp(a) Associations With Aortic Valve Stenosis Incidence: Insights From the EPIC-Norfolk Prospective Population Study. *Journal of the American Heart Association*, **2019**, 8, e013020	6	7
200	Validation of the Systematic COronary Risk Evaluation - Older Persons (SCORE-OP) in the EPIC-Norfolk prospective population study. *International Journal of Cardiology*, **2019**, 293, 226-230	3.2	6
199	Aortic dissection and prophylactic surgery in congenital heart disease. *International Journal of Cardiology*, **2019**, 274, 113-116	3.2	10
198	Smoking cessation after nurse-coordinated referral to a comprehensive lifestyle programme in patients with coronary artery disease: a substudy of the RESPONSE-2 trial. *European Journal of Cardiovascular Nursing*, **2019**, 18, 113-121	3.3	7
197	Myocardial fibrosis predicts adverse outcome after MitraClip implantation. *Catheterization and Cardiovascular Interventions*, **2019**, 93, 1146-1149	2.7	5
196	Can stress echocardiography identify patients who will benefit from percutaneous mitral valve repair?. *International Journal of Cardiovascular Imaging*, **2019**, 35, 645-651	2.5	4
195	Myocardial fibrosis as an early feature in phospholamban p.Arg14del mutation carriers: phenotypic insights from cardiovascular magnetic resonance imaging. *European Heart Journal Cardiovascular Imaging*, **2019**, 20, 92-100	4.1	29
194	The prognostic value of heart rate recovery in patients with coronary artery disease: A systematic review and meta-analysis. *American Heart Journal*, **2018**, 199, 163-169	4.9	13
193	Elevated lipoprotein(a) levels are associated with coronary artery calcium scores in asymptomatic individuals with a family history of premature atherosclerotic cardiovascular disease. *Journal of Clinical Lipidology*, **2018**, 12, 597-603.e1	4.9	18
192	Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. *Circulation*, **2018**, 138, 770-781	16.7	65
191	Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease. *Heart*, **2018**, 104, 1699-1705	5.1	11
190	Aortic valve stenosis and aortic diameters determine the extent of increased wall shear stress in bicuspid aortic valve disease. *Journal of Magnetic Resonance Imaging*, **2018**, 48, 522-530	5.6	37
189	Genetics, Clinical Features, and Long-Term Outcome of Noncompaction Cardiomyopathy. *Journal of the American College of Cardiology*, **2018**, 71, 711-722	15.1	158
188	Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk. *Journal of Clinical Lipidology*, **2018**, 12, 130-136	4.9	27

187	Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting. *European Heart Journal*, **2018**, 39, 2589-2596	9.5	56
186	Life's simple 7 and calcific aortic valve stenosis incidence in apparently healthy men and women. *International Journal of Cardiology*, **2018**, 269, 226-228	3.2	10
185	Elixhauser Comorbidity Score Is the Best Risk Score in Predicting Survival After Mitraclip Implantation. *Structural Heart*, **2018**, 2, 53-57	0.6	7
184	Effect of Long-Term Low Lipoproteins on Neurocognitive Function. *Journal of the American College of Cardiology*, **2018**, 72, 1176-1177	15.1	1
183	Advanced cardiac MRI techniques for evaluation of left-sided valvular heart disease. *Journal of Magnetic Resonance Imaging*, **2018**, 48, 318-329	5.6	14
182	Impact of physical activity on the risk of cardiovascular disease in middle-aged and older adults: EPIC Norfolk prospective population study. *European Journal of Preventive Cardiology*, **2018**, 25, 200-208	3.9	54
181	Effect of Losartan on Right Ventricular Dysfunction: Results From the Double-Blind, Randomized REDEFINE Trial (Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-Angiotensin-Aldosterone System) in Adults With Repaired Tetralogy of Fallot. *Circulation*, **2018**, 137, 1463-1471	16.7	25
180	Four-dimensional flow MRI of stented versus stentless aortic valve bioprostheses. *European Radiology*, **2018**, 28, 257-264	8	11
179	Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study. *Journal of Clinical Lipidology*, **2018**, 12, 1493-1501.e11	4.9	6
178	Aldosterone Pathway Blockade to Prevent Atrial Fibrillation: A Systematic Review and Meta-Analysis. *International Journal of Cardiology*, **2017**, 231, 155-161	3.2	50
177	Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk: The EPIC-Norfolk Prospective Population Study. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2017**, 37, 1206-1212	9.4	35
176	Response to "comment on "aldosterone pathway blockade to prevent atrial fibrillation: A systematic review and meta-analysis" by Neefs et al.". *International Journal of Cardiology*, **2017**, 242, 23	3.2	0
175	Lipoprotein(a) Improves Cardiovascular Risk Prediction Based on Established Risk Algorithms. *Journal of the American College of Cardiology*, **2017**, 69, 1513-1515	15.1	28
174	An Evidence-Based Guide to Cholesterol-Lowering Guidelines. *Canadian Journal of Cardiology*, **2017**, 33, 343-349	3.8	13
173	Nurse-coordinated care improves the achievement of LDL cholesterol targets through more intensive medication titration. *Open Heart*, **2017**, 4, e000607	3	3
172	Association of High-Density Lipoprotein-Cholesterol Versus Apolipoprotein A-I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer-Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study. *Journal of the American Heart Association*, **2017**, 6,	6	9
171	Coronary Artery Disease Affects Symptomatology of Aortic Valve Stenosis. *Journal of the American College of Cardiology*, **2017**, 70, 1103-1104	15.1	1
170	Systolic anterior motion of the tricuspid valve in a patient with hypertrophic obstructive cardiomyopathy. *Interactive Cardiovascular and Thoracic Surgery*, **2017**, 25, 496-497	1.8	2

169	Community-Based Lifestyle Intervention in Patients With Coronary Artery Disease: The RESPONSE-2 Trial. *Journal of the American College of Cardiology*, **2017**, 70, 318-327	15.1	47
168	The Dutch SCORE-based risk charts seriously underestimate the risk of cardiovascular disease. *Netherlands Heart Journal*, **2017**, 25, 173-180	2.2	2
167	Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: The EPIC-Norfolk prospective population study. *Atherosclerosis*, **2017**, 256, 47-52	3.1	38
166	Carriers of the PCSK9 R46L Variant Are Characterized by an Antiatherogenic Lipoprotein Profile Assessed by Nuclear Magnetic Resonance Spectroscopy-Brief Report. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2017**, 37, 43-48	9.4	19
165	Very low LDL-cholesterol concentrations achieved: which target is next?. *Lancet, The*, **2017**, 390, 1930-1931	47	3
164	Human Cardiac P-MR Spectroscopy at 3 Tesla Cannot Detect Failing Myocardial Energy Homeostasis during Exercise. *Frontiers in Physiology*, **2017**, 8, 939	4.6	16
163	Ideal cardiovascular health and risk of cardiovascular events in the EPIC-Norfolk prospective population study. *European Journal of Preventive Cardiology*, **2016**, 23, 986-94	3.9	36
162	Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study. *Journal of Lipid Research*, **2016**, 57, 697-705	6.3	22
161	C-Reactive Protein Identifies Low-Risk Metabolically Healthy Obese Persons: The European Prospective Investigation of Cancer-Norfolk Prospective Population Study. *Journal of the American Heart Association*, **2016**, 5,	6	17
160	Effective components of nurse-coordinated care to prevent recurrent coronary events: a systematic review and meta-analysis. *Heart*, **2016**, 102, 50-6	5.1	23
159	Habitual chocolate consumption and the risk of incident heart failure among healthy men and women. *Nutrition, Metabolism and Cardiovascular Diseases*, **2016**, 26, 722-34	4.5	10
158	Detailed characterization of familial idiopathic ventricular fibrillation linked to the DPP6 locus. *Heart Rhythm*, **2016**, 13, 905-12	6.7	28
157	Coronary artery calcification score as tool for risk assessment among families with premature coronary artery disease. *Atherosclerosis*, **2016**, 245, 155-60	3.1	7
156	Heterogeneous impact of classic atherosclerotic risk factors on different arterial territories: the EPIC-Norfolk prospective population study. *European Heart Journal*, **2016**, 37, 880-9	9.5	24
155	Estimated 10-year cardiovascular mortality seriously underestimates overall cardiovascular risk. *Heart*, **2016**, 102, 63-8	5.1	32
154	Meta-analysis of genome-wide association studies of HDL cholesterol response to statins. *Journal of Medical Genetics*, **2016**, 53, 835-845	5.8	28
153	Dilation of the Aorta Ascendens Forms Part of the Clinical Spectrum of HCN4 Mutations. *Journal of the American College of Cardiology*, **2016**, 67, 2313-2315	15.1	20
152	Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and Collaborative Atorvastatin Diabetes Study. *Circulation: Cardiovascular Quality and Outcomes*, **2016**, 9, 213-21	5.8	8

151	Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population. *Circulation*, **2016**, 134, 1419-1429	16.7	104
150	Transition from paediatric to adult care of adolescent patients with congenital heart disease: a pathway to optimal care. *Netherlands Heart Journal*, **2016**, 24, 682-690	2.2	4
149	High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease. *Heart*, **2015**, 101, 356-62	5.1	33
148	Habitual chocolate consumption and risk of cardiovascular disease among healthy men and women. *Heart*, **2015**, 101, 1279-87	5.1	53
147	Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP as a Target to Lower CVD Risk: Suspension of Disbelief?. *Circulation*, **2015**, 132, 433-40	16.7	21
146	Community-based comprehensive lifestyle programs in patients with coronary artery disease: Objectives, design and expected results of Randomized Evaluation of Secondary Prevention by Outpatient Nurse SpEcialists 2 trial (RESPONSE 2). *American Heart Journal*, **2015**, 170, 216-22	4.9	9
145	Platypnoea-orthodeoxia syndrome, an underdiagnosed cause of hypoxaemia: four cases and the possible underlying mechanisms. *Netherlands Heart Journal*, **2015**, 23, 539-45	2.2	8
144	Smoking cessation after an acute coronary syndrome: immediate quitters are successful quitters. *Netherlands Heart Journal*, **2015**, 23, 600-7	2.2	26
143	Non-high-density lipoprotein cholesterol: current status as cardiovascular marker. *Current Opinion in Lipidology*, **2015**, 26, 502-10	4.4	50
142	The Systematic COronary Risk Evaluation (SCORE) in a large UK population: 10-year follow-up in the EPIC-Norfolk prospective population study. *European Journal of Preventive Cardiology*, **2015**, 22, 119-26	3.9	14
141	Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. *Lancet Diabetes and Endocrinology,the*, **2015**, 3, 507-13	18.1	300
140	PLA2G10 Gene Variants, sPLA2 Activity, and Coronary Heart Disease Risk. *Circulation: Cardiovascular Genetics*, **2015**, 8, 356-62		15
139	Reply: statin-induced low low-density lipoprotein cholesterol level: is lower better?. *Journal of the American College of Cardiology*, **2015**, 65, 109	15.1	
138	The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. *European Heart Journal*, **2014**, 35, 960-8	9.5	222
137	Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL). *American Journal of Cardiology* , **2014**, 113, 1378-82	3	21
136	The association between circulating lipoprotein(a) and type 2 diabetes: is it causal?. *Diabetes*, **2014**, 63, 332-342	0.9	60
135	Added value of hybrid myocardial perfusion SPECT and CT coronary angiography in the diagnosis of coronary artery disease. *European Heart Journal Cardiovascular Imaging*, **2014**, 15, 1281-8	4.1	23
134	Novel genetic approach to investigate the role of plasma secretory phospholipase A2 (sPLA2)-V isoenzyme in coronary heart disease: modified Mendelian randomization analysis using PLA2G5 expression levels. *Circulation: Cardiovascular Genetics*, **2014**, 7, 144-50		21

133	Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. *Journal of the American College of Cardiology*, **2014**, 64, 485-94	15.1	372
132	Unroofed coronary sinus newly diagnosed in adult patients after corrected congenital heart disease. *Netherlands Heart Journal*, **2014**, 22, 240-5	2.2	4
131	Common genetic variants do not associate with CAD in familial hypercholesterolemia. *European Journal of Human Genetics*, **2014**, 22, 809-13	5.3	2
130	Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. *Nature Communications*, **2014**, 5, 5068	17.4	160
129	Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort. *Circulation: Cardiovascular Genetics*, **2014**, 7, 304-10		160
128	Impact of abdominal obesity and systemic hypertension on risk of coronary heart disease in men and women: the EPIC-Norfolk Population Study. *Journal of Hypertension*, **2014**, 32, 2224-30; discussion 2230	1.9	8
127	Clinical and biological relevance of statin-mediated changes in HDL metabolism. *Current Atherosclerosis Reports*, **2014**, 16, 379	6	0
126	Reduction of heart volume during neoadjuvant chemoradiation in patients with resectable esophageal cancer.. *Journal of Clinical Oncology*, **2014**, 32, 4044-4044	2.2	
125	Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. *Journal of the American College of Cardiology*, **2013**, 62, 1966-1976	15.1	91
124	Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. *Circulation*, **2013**, 128, 1504-12	16.7	135
123	Hybrid myocardial perfusion SPECT/CT coronary angiography and invasive coronary angiography in patients with stable angina pectoris lead to similar treatment decisions. *Heart*, **2013**, 99, 188-94	5.1	35
122	Clinical implications of JUPITER in a contemporary European population: the EPIC-Norfolk prospective population study. *European Heart Journal*, **2013**, 34, 1350-7	9.5	2
121	Response to letter by Balta et al. *International Journal of Cardiology*, **2013**, 169, 89	3.2	2
120	Rates and determinants of progressive aortic valve dysfunction in aortic coarctation. *International Journal of Cardiology*, **2013**, 167, 2841-5	3.2	5
119	Reply: To PMID 23219296. *Journal of the American College of Cardiology*, **2013**, 61, 1934	15.1	4
118	Red cell distribution width is associated with physical inactivity and heart failure, independent of established risk factors, inflammation or iron metabolism; the EPIC-Norfolk study. *International Journal of Cardiology*, **2013**, 168, 3550-5	3.2	49
117	Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. *Journal of the American College of Cardiology*, **2013**, 61, 148-52	15.1	130
116	Usefulness of coronary calcium scoring to myocardial perfusion SPECT in the diagnosis of coronary artery disease in a predominantly high risk population. *International Journal of Cardiovascular Imaging*, **2013**, 29, 677-84	2.5	2

115	Incremental diagnostic accuracy of hybrid SPECT/CT coronary angiography in a population with an intermediate to high pre-test likelihood of coronary artery disease. *European Heart Journal Cardiovascular Imaging*, **2013**, 14, 642-9	4.1	41
114	The authors reply. *Heart*, **2013**, 99, 1136-7	5.1	1
113	C-reactive protein, fatal and nonfatal coronary artery disease, stroke, and peripheral artery disease in the prospective EPIC-Norfolk cohort study. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2013**, 33, 2888-94	9.4	34
112	A comparative analysis of three widely used lipid management guidelines in the EPIC-Norfolk cohort. *European Journal of Preventive Cardiology*, **2013**, 20, 98-106	3.9	2
111	High-sensitivity troponin T is associated with poor outcome in adults with pulmonary arterial hypertension due to congenital heart disease. *Congenital Heart Disease*, **2013**, 8, 520-6	3.1	29
110	Non-HDL cholesterol vs. apo B for risk of coronary heart disease in healthy individuals: the EPIC-Norfolk prospective population study. *European Journal of Clinical Investigation*, **2013**, 43, 1009-15	4.6	23
109	High-dose statin therapy in patients with stable coronary artery disease: treating the right patients based on individualized prediction of treatment effect. *Circulation*, **2013**, 127, 2485-93	16.7	34
108	Zero coronary calcium in the presence of severe isolated left main stenosis detected by CT coronary angiography in a patient with typical angina and equivocal myocardial perfusion SPECT. *Journal of Nuclear Cardiology*, **2012**, 19, 165-8	2.1	4
107	The interleukin-6 pathway and atherosclerosis. *Lancet, The*, **2012**, 379, 1176-8	40	38
106	Surgical versus percutaneous treatment of aortic coarctation: new standards in an era of transcatheter repair. *Expert Review of Cardiovascular Therapy*, **2012**, 10, 1517-31	2.5	26
105	On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). *Journal of the American College of Cardiology*, **2012**, 59, 1521-8	15.1	72
104	Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study. *Journal of the American College of Cardiology*, **2012**, 59, 1778-84	15.1	51
103	Percutaneous treatment of native aortic coarctation in adults. *Netherlands Heart Journal*, **2012**, 20, 339-40	2.2	1
102	Two cases of aorto-right atrial tunnel: clinical presentation, imaging and percutaneous closure. *Netherlands Heart Journal*, **2012**, 20, 509-12	2.2	3
101	Validation of a model to investigate the effects of modifying cardiovascular disease (CVD) risk factors on the burden of CVD: the rotterdam ischemic heart disease and stroke computer simulation (RISC) model. *BMC Medicine*, **2012**, 10, 158	11.4	8
100	The role of non-HDL cholesterol in risk stratification for coronary artery disease. *Current Atherosclerosis Reports*, **2012**, 14, 130-4	6	45
99	The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies. *Circulation: Cardiovascular Genetics*, **2012**, 5, 51-7		17
98	Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2012**, 32, 3058-65	9.4	97

97	Relationship between atorvastatin dose and the harm caused by torcetrapib. *Journal of Lipid Research*, **2012**, 53, 2436-42	6.3	8
96	Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. *JAMA - Journal of the American Medical Association*, **2012**, 307, 1302-9	27.4	512
95	Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study. *Circulation*, **2012**, 125, 1979-87	16.7	114
94	Lipid-related markers and cardiovascular disease prediction. *JAMA - Journal of the American Medical Association*, **2012**, 307, 2499-506	27.4	271
93	Inflammatory biomarkers, physical activity, waist circumference, and risk of future coronary heart disease in healthy men and women. *European Heart Journal*, **2011**, 32, 336-44	9.5	80
92	Physical activity, metabolic syndrome, and coronary risk: the EPIC-Norfolk prospective population study. *European Journal of Cardiovascular Prevention and Rehabilitation*, **2011**, 18, 209-17		39
91	Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. *Nature Genetics*, **2011**, 43, 1131-8	36.3	415
90	Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. *Diabetes*, **2011**, 60, 2624-34	0.9	285
89	Hypertriglyceridemic waist: missing piece of the global cardiovascular risk assessment puzzle?. *Clinical Lipidology*, **2011**, 6, 639-651		4
88	Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. *Nature Genetics*, **2011**, 43, 333-8	36.3	1394
87	Adiponectin and risk of coronary heart disease in apparently healthy men and women (from the EPIC-Norfolk Prospective Population Study). *American Journal of Cardiology*, **2011**, 108, 367-73	3	32
86	Patent ductus arteriosus in adults - indications and possibilities for closure. *Netherlands Heart Journal*, **2011**, 19, 297-300	2.2	3
85	Per-operative stent placement in the right pulmonary artery; a hybrid technique for the management of pulmonary artery branch stenosis at the time of pulmonary valve replacement in adult Fallot patients. *Netherlands Heart Journal*, **2011**, 19, 432-5	2.2	6
84	Percutaneous treatment of native aortic coarctation in adults. *Netherlands Heart Journal*, **2011**, 19, 436-9	2.2	9
83	Advanced therapy for pulmonary arterial hypertension due to congenital heart disease: a clinical perspective in a new therapeutic era. *Netherlands Heart Journal*, **2011**, 19, 509-13	2.2	9
82	Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study. *Journal of Lipid Research*, **2011**, 52, 1829-36	6.3	96
81	Lipid parameters for measuring risk of cardiovascular disease. *Nature Reviews Cardiology*, **2011**, 8, 197-206	14.8	144
80	Prospective study of insulin-like growth factor-I, insulin-like growth factor-binding protein 3, genetic variants in the IGF1 and IGFBP3 genes and risk of coronary artery disease. *International Journal of Molecular Epidemiology and Genetics*, **2011**, 2, 261-85	0.9	8

79	Comprehensive Lipid Profiling Beyond LDL **2011**, 107-118		1
78	Initial thyroid status and cardiovascular risk factors: the EPIC-Norfolk prospective population study. *Clinical Endocrinology*, **2010**, 72, 404-10	3.4	115
77	Lipid assessment, metabolic syndrome and coronary heart disease risk. *European Journal of Clinical Investigation*, **2010**, 40, 1081-93	4.6	24
76	Physical inactivity, abdominal obesity and risk of coronary heart disease in apparently healthy men and women. *International Journal of Obesity*, **2010**, 34, 340-7	5.5	55
75	Biological, clinical and population relevance of 95 loci for blood lipids. *Nature*, **2010**, 466, 707-13	50.4	2742
74	Genetic variation at the phospholipid transfer protein locus affects its activity and high-density lipoprotein size and is a novel marker of cardiovascular disease susceptibility. *Circulation*, **2010**, 122, 470-7	16.7	75
73	Chemokine ligand 2 genetic variants, serum monocyte chemoattractant protein-1 levels, and the risk of coronary artery disease. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2010**, 30, 1460-6	9.4	16
72	PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry. *Circulation*, **2010**, 121, 2284-93	16.7	90
71	Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms. *Circulation*, **2010**, 121, 52-62	16.7	76
70	Comparison between gradient gel electrophoresis and nuclear magnetic resonance spectroscopy in estimating coronary heart disease risk associated with LDL and HDL particle size. *Clinical Chemistry*, **2010**, 56, 789-98	5.5	29
69	The relationship between plasma angiopoietin-like protein 4 levels, angiopoietin-like protein 4 genotype, and coronary heart disease risk. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2010**, 30, 2277-82	9.4	53
68	Plasma levels of lecithin:cholesterol acyltransferase and risk of future coronary artery disease in apparently healthy men and women: a prospective case-control analysis nested in the EPIC-Norfolk population study. *Journal of Lipid Research*, **2010**, 51, 416-21	6.3	50
67	Genetic variants influencing circulating lipid levels and risk of coronary artery disease. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2010**, 30, 2264-76	9.4	318
66	The hypertriglyceridemic-waist phenotype and the risk of coronary artery disease: results from the EPIC-Norfolk prospective population study. *Cmaj*, **2010**, 182, 1427-32	3.5	120
65	Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. *Journal of the American College of Cardiology*, **2010**, 56, 946-55	15.1	120
64	Metabolic dyslipidemia and risk of future coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. *International Journal of Cardiology*, **2010**, 143, 399-404	3.2	29
63	Physical activity, the Framingham risk score and risk of coronary heart disease in men and women of the EPIC-Norfolk study. *Atherosclerosis*, **2010**, 209, 261-5	3.1	25
62	Lack of association between common genetic variation in endothelial lipase (LIPG) and the risk for CAD and DVT. *Atherosclerosis*, **2010**, 211, 558-64	3.1	35

61	C-reactive protein and cardiovascular risk: more fuel to the fire. *Lancet, The*, **2010**, 375, 95-6	40	17
60	C-reactive protein measurement and cardiovascular disease Authors' reply. *Lancet, The*, **2010**, 375, 1077-1078	40	1
59	Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. *Lancet, The*, **2010**, 375, 1634-9	40	520
58	HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. *Lancet, The*, **2010**, 376, 333-9	40	178
57	Rimonabant: obituary for a wonder drug. *Lancet, The*, **2010**, 376, 489-90	40	16
56	C-reactive protein is a mediator of cardiovascular disease. *European Heart Journal*, **2010**, 31, 2087-91	9.5	135
55	Improving risk stratification for cardiovascular disease. *Expert Review of Cardiovascular Therapy*, **2010**, 8, 1091-3	2.5	2
54	Family history of premature coronary heart disease and risk prediction in the EPIC-Norfolk prospective population study. *Heart*, **2010**, 96, 1985-9	5.1	79
53	Toll-like receptor 4 gene polymorphisms show no association with the risk of clinical or angiographic restenosis after percutaneous coronary intervention. *Pharmacogenetics and Genomics*, **2010**, 20, 544-52	1.9	6
52	Should we change our lipid management strategies to focus on non-high-density lipoprotein cholesterol?. *Current Opinion in Cardiology*, **2010**, 25, 622-6	2.1	6
51	Both paraoxonase-1 genotype and activity do not predict the risk of future coronary artery disease; the EPIC-Norfolk Prospective Population Study. *PLoS ONE*, **2009**, 4, e6809	3.7	37
50	Retinol-binding protein 4 and prediction of incident coronary events in healthy men and women. *Journal of Clinical Endocrinology and Metabolism*, **2009**, 94, 255-60	5.6	51
49	Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2009**, 29, 975-80	9.4	61
48	Inflammatory biomarkers and the prediction of coronary events among people at intermediate risk: the EPIC-Norfolk prospective population study. *Heart*, **2009**, 95, 1682-7	5.1	34
47	Prolactin levels and the risk of future coronary artery disease in apparently healthy men and women. *Circulation: Cardiovascular Genetics*, **2009**, 2, 389-95		35
46	Is myeloperoxidase a useful marker to predict the risk of cardiovascular events?. *Current Cardiovascular Risk Reports*, **2009**, 3, 137-143	0.9	2
45	Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. *Journal of the American College of Cardiology*, **2009**, 55, 35-41	15.1	220
44	High-density lipoprotein particle size and concentration and coronary risk. *Annals of Internal Medicine*, **2009**, 150, 84-93	8	167

43	HDL particle size and the risk of coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. *Atherosclerosis*, **2009**, 206, 276-81	3.1	86
42	Bayesian meta-analysis of genetic association studies with different sets of markers. *American Journal of Human Genetics*, **2008**, 82, 859-72	11	49
41	High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. *Journal of the American College of Cardiology*, **2008**, 51, 634-42	15.1	264
40	ANGPTL4 E40K and T266M: effects on plasma triglyceride and HDL levels, postprandial responses, and CHD risk. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2008**, 28, 2319-25	9.4	75
39	Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. *Circulation*, **2008**, 117, 3002-9	16.7	357
38	Evaluation of the Framingham risk score in the European Prospective Investigation of Cancer-Norfolk cohort: does adding glycated hemoglobin improve the prediction of coronary heart disease events?. *Archives of Internal Medicine*, **2008**, 168, 1209-16		49
37	Major depression, C-reactive protein, and incident ischemic heart disease in healthy men and women. *Psychosomatic Medicine*, **2008**, 70, 850-5	3.7	25
36	Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. *Journal of the American College of Cardiology*, **2007**, 49, 547-53	15.1	198
35	Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. *Journal of the American College of Cardiology*, **2007**, 50, 159-65	15.1	483
34	Differential leucocyte count and the risk of future coronary artery disease in healthy men and women: the EPIC-Norfolk Prospective Population Study. *Journal of Internal Medicine*, **2007**, 262, 678-89	10.8	61
33	Apolipoprotein A-II is inversely associated with risk of future coronary artery disease. *Circulation*, **2007**, 116, 2029-35	16.7	88
32	Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2007**, 27, 1177-83	9.4	89
31	Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the EPIC-Norfolk prospective population study. *European Heart Journal*, **2007**, 28, 2770-7	9.5	44
30	Arterial thrombosis and the role of thrombophilia. *Seminars in Thrombosis and Hemostasis*, **2007**, 33, 588-96	3.9	76
29	Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. *Circulation*, **2007**, 115, 450-8	16.7	1001
28	Plasma levels of plant sterols and the risk of coronary artery disease: the prospective EPIC-Norfolk Population Study. *Journal of Lipid Research*, **2007**, 48, 139-44	6.3	86
27	Body fat distribution and risk of coronary heart disease in men and women in the European Prospective Investigation Into Cancer and Nutrition in Norfolk cohort: a population-based prospective study. *Circulation*, **2007**, 116, 2933-43	16.7	352
26	Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. *Annals of Internal Medicine*, **2007**, 146, 640-8	8	116

25	Apolipoprotein A-V, triglycerides and risk of coronary artery disease: the prospective Epic-Norfolk Population Study. *Journal of Lipid Research*, **2006**, 47, 2064-70	6.3	76
24	Serum levels of mannose-binding lectin and the risk of future coronary artery disease in apparently healthy men and women. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2006**, 26, 2345-50	9.4	54
23	Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2006**, 26, 706-15	9.4	56
22	Physical activity, C-reactive protein levels and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. *European Journal of Cardiovascular Prevention and Rehabilitation*, **2006**, 13, 970-6		16
21	Serum lipoprotein lipase concentration and risk for future coronary artery disease: the EPIC-Norfolk prospective population study. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2006**, 26, 637-42	9.4	54
20	C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003. *Atherosclerosis*, **2006**, 187, 415-22	3.1	134
19	Common variants of multiple genes that control reverse cholesterol transport together explain only a minor part of the variation of HDL cholesterol levels. *Clinical Genetics*, **2006**, 69, 263-70	4	41
18	Fibrinogen plasma levels modify the association between the factor XIII Val34Leu variant and risk of coronary artery disease: the EPIC-Norfolk prospective population study. *Journal of Thrombosis and Haemostasis*, **2006**, 4, 2204-9	15.4	20
17	Tissue factor serum levels and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. *Journal of Thrombosis and Haemostasis*, **2006**, 4, 2391-6	15.4	9
16	Plasma concentrations of ascorbic acid and C-reactive protein, and risk of future coronary artery disease, in apparently healthy men and women: the EPIC-Norfolk prospective population study. *British Journal of Nutrition*, **2006**, 96, 516-22	3.6	41
15	Inherited disorders of HDL metabolism and atherosclerosis. *Current Opinion in Lipidology*, **2005**, 16, 139-45	4.4	84
14	Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. *Circulation*, **2005**, 111, 278-87	16.7	266
13	Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2005**, 25, 839-46	9.4	85
12	Relationship between in vitro lipopolysaccharide-induced cytokine response in whole blood, angiographic in-stent restenosis, and toll-like receptor 4 gene polymorphisms. *Clinical Chemistry*, **2005**, 51, 516-21	5.5	12
11	Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study. *Circulation*, **2004**, 110, 1418-23	16.7	188
10	IL-8 plasma concentrations and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2004**, 24, 1503-8	9.4	150
9	Interaction between a genetic variant of the platelet fibrinogen receptor and fibrinogen levels in determining the risk of cardiovascular events. *American Heart Journal*, **2004**, 147, 181-6	4.9	20
8	Macrophage migration inhibitory factor and the risk of myocardial infarction or death due to coronary artery disease in adults without prior myocardial infarction or stroke: the EPIC-Norfolk Prospective Population study. *American Journal of Medicine*, **2004**, 117, 390-7	2.4	73

7	CETP gene variation: relation to lipid parameters and cardiovascular risk. *Current Opinion in Lipidology*, **2004**, 15, 393-8	4.4	48
6	Role of CETP inhibitors in the treatment of dyslipidemia. *Current Opinion in Lipidology*, **2004**, 15, 631-6	4.4	40
5	Molecular variation at the apolipoprotein B gene locus in relation to lipids and cardiovascular disease: a systematic meta-analysis. *Human Genetics*, **2003**, 113, 417-25	6.3	47
4	Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. *Circulation*, **2003**, 107, 2416-21	16.7	198
3	Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. *Journal of Lipid Research*, **2003**, 44, 1080-93	6.3	120
2	Thrombospondin-2 polymorphism is associated with a reduced risk of premature myocardial infarction. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2002**, 22, e24-7	9.4	46
1	Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. *Circulation*, **2001**, 104, 3063-8	16.7	164